- Home
- USAU vs FHTX Comparison
USAU vs FHTX Comparison
Compare USAU & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | USAU | FHTX |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Medicinal Chemicals and Botanical Products |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 283.5M | 323.4M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | USAU | FHTX |
|---|---|---|
| Price | $17.83 | $4.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $22.83 | $11.50 |
| AVG Volume (30 Days) | ★ 194.3K | 101.4K |
| Earning Date | 03-16-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.32 |
| EPS | N/A | ★ N/A |
| Revenue | $17,402,000.00 | ★ $30,909,000.00 |
| Revenue This Year | N/A | $8.89 |
| Revenue Next Year | N/A | $20.13 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 36.75 |
| 52 Week Low | $9.75 | $3.27 |
| 52 Week High | $23.72 | $6.95 |
Technical Indicators
Market Signals| Indicator | USAU | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 60.36 | 37.98 |
| Support Level | $16.35 | $3.65 |
| Resistance Level | $17.89 | $5.82 |
| Average True Range (ATR) | 0.70 | 0.29 |
| MACD | 0.13 | -0.07 |
| Stochastic Oscillator | 83.80 | 21.26 |
Price Performance
Historical ComparisonAbout USAU U.S. Gold Corp.
U.S. Gold Corp is an exploration and development company that owns certain mining leases and other mineral rights comprising the CK Gold Project in Wyoming, the Keystone Project in Nevada, and the Challis Gold Project in Idaho.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.